Research programme: interferon alpha-2b polysialic - Xenetic Biosciences/SynBio

Drug Profile

Research programme: interferon alpha-2b polysialic - Xenetic Biosciences/SynBio

Alternative Names: InferoXen; Interferon alpha-2b - Xenetic Biosciences; SYN20110410RU

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Lipoxen Technologies
  • Developer SynBio; Xenetic Biosciences
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in United Kingdom (Parenteral)
  • 16 Jun 2014 Interferon alpha-2b polysialic licensed to SynBio prior to April 2014
  • 30 Apr 2014 Preclinical trials in Hepatitis C in Russia (Parenteral) prior to April 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top